These consistent outcomes in various clinical settings relating to plasma copeptin level suggest that strategies for prognostic risk stratification beyond the use of well-known risk factors such as age and stroke severity are necessary for determining early therapeutic interventions, aggressiveness of care, and rehabilitation. The gene discussed is AVP; the disease is stroke disorder.